Pasi Jänne was recently recognised with the ACS 2024 Medal of Honour Award – Dana-Farber Cancer Institute
Dana-Farber Cancer Institute shared a post on LinkedIn:
“Pasi Jänne, senior vice president for Translational Medicine, was recently recognised with the American Cancer Society (ACS) 2024 Medal of Honour Award. The award, which is the most prestigious honour given by the ACS, recognises individuals or foundations that have made valuable contributions in basic research, cancer control, clinical research, or philanthropy.
Jänne’s research has led to major advances in the treatment of lung cancer. His lab focuses on identifying genetic factors that drive cancer growth and enable tumors to resist treatment. He was a co-discoverer of epidermal growth factor receptor (EGFR) mutations and has led the development of therapeutic strategies for patients with EGFR-mutant lung cancer.
‘In addition to Dr. Jänne‘s steadfast commitment to developing more precise and durable therapies for patients with lung cancer, it is his visionary thinking, collaborative mindset, dedication to mentoring, and strong leadership in oncology that earned him this recognition,’ shares William Dahut, Chief Scientific Officer of the ACS.
Jänne joins a distinguished group of scientists and organizations that have received the ACS Medal of Honor since it was established in 1949.
‘The American Cancer Society has a long history of supporting some of the most proficient cancer researchers in the world, and to be part of that group is an honor,’ Jänne remarks. ‘While we‘ve made significant progress in lung cancer research, we owe it to patients, survivors, and their caregivers to further research and advance the ACS’s mission of saving more lives.’ ”